Latisse

Name: Latisse

Warnings

Contraindications

Hypersensitivity

Cautions

Caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

Contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses

Caution in active intraocular inflammation (e.g., uveitis)

Take soft contact lenses out when applying, reinsert at least 15 min later

Bacterial keratitis may result from inadvertent contamination of multi-dose ophthalmic solutions

May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes

Not recommended for patients <16 years

Latisse Drug Class

Latisse is part of the drug class:

  • Prostaglandin analogues

Other Requirements

  • Store Latisse at 36°-77°F (2°-25°C).
  • Keep this and all medicines out of the reach of children.

What should I avoid while using bimatoprost topical ophthalmic?

Avoid getting this medicine on any skin areas outside the base of your eyelashes. Increased hair growth can occur on any skin surface that comes into contact with bimatoprost topical ophthalmic.

If this medication gets directly in your eyes, rinse with water.

How is this medicine (Latisse) best taken?

Use Latisse as ordered by your doctor. Read all information given to you. Follow all instructions closely.

  • To gain the most benefit, do not miss doses.
  • Use as you have been told, even if your signs get better.
  • For the eyelid only.
  • Wash your hands before and after use.
  • Take out contact lenses before using this medicine. Lenses may be put back in 15 minutes after Latisse is given. Do not put contacts back in if your eyes are irritated or infected.
  • Do not touch the container tip to the eye, lid, or other skin.
  • Do not touch the applicator tip to the eye, other skin, or any other surface.
  • Clean your face and take off make-up.
  • Put on upper eyelid using only the applicator that comes with it.
  • Use a new applicator for the other eye.
  • Do not use the applicators more than 1 time.
  • Do not put on lower lashes.
  • Blot extra solution from the eyelid.

What do I do if I miss a dose?

  • Use a missed dose as soon as you think about it.
  • If it is close to the time for your next dose, skip the missed dose and go back to your normal time.
  • Do not use 2 doses at the same time or extra doses.

What are some side effects that I need to call my doctor about right away?

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Change in eyesight, eye pain, or very bad eye irritation.
  • If bright lights bother your eyes.
  • Eye discharge.
  • Eye color may change to a brown color. This change may be long-lasting. Eye color changes may happen a few months to years after starting this medicine. If eye color changes, call the doctor.

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Nightly Application

Inform patients that Latisse® (bimatoprost ophthalmic solution) should be applied every night using only the accompanying sterile applicators. They should start by ensuring their face is clean, all makeup is removed, and their contact lenses removed (if applicable). Then, carefully place one drop of Latisse® solution on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. If any Latisse® solution gets into the eye proper, it will not cause harm. The eye should not be rinsed.

Additional applications of Latisse® will not increase the growth of eyelashes.

Inform patients not to apply to the lower eyelash line. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material.

The onset of effect is gradual but is not significant in the majority of patients until 2 months. Counsel patients that the effect is not permanent and can be expected to gradually return to the original level upon discontinuation of treatment with Latisse®.

Handling the Bottle and Applicator

Instruct patients that the Latisse® bottle must be maintained intact and to avoid allowing the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination of the bottle or applicator by common bacteria known to cause ocular infections. Instruct patients to only use the applicator supplied with the product once and then discard since reuse could result in using a contaminated applicator. Serious infections may result from using contaminated solutions or applicators.

Potential for Intraocular Pressure Effects

Latisse® may lower intraocular pressure although not to a level that will cause clinical harm.

In patients using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of Latisse® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs for IOP reduction should only use Latisse® after consulting with their physician.

Potential for Eyelid Skin Darkening

Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of Latisse®.

Potential for Iris Darkening

Advise patients about the potential for increased brown iris pigmentation which is likely to be permanent. Increased iris pigmentation has occurred when bimatoprost solution was administered.

Potential for Unexpected Hair Growth or Eyelash Changes

Inform patients of the possibility of hair growth occurring outside of the target treatment area if Latisse® repeatedly touches the same area of skin outside the treatment area. They should also be informed of the possibility of disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are likely reversible upon discontinuation of treatment.

When to Seek Physician Advice

Advise patients that if they develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of Latisse®. Patients on IOP-lowering medications should not use Latisse® without prior consultation with their physician.

Use with Contact Lenses

Advise patients that Latisse® solution contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to application of Latisse® and may be reinserted 15 minutes following its administration.

© 2017 Allergan. All rights reserved.
All trademarks are the property of their respective owners.
Patented. See: www.allergan.com/patents
Irvine, CA 92612
Made in the U.S.A.

72303US17

------Cut---Here---✂-------------------------------------------------------------------------------------------------------------

FDA-approved Patient Labeling

PATIENT INFORMATION

Latisse® [la teece]

(bimatoprost ophthalmic solution) 0.03%

Read the Patient Information that comes with Latisse® before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your physician about your treatment.

What is hypotrichosis of the eyelashes?

Hypotrichosis is another name for having inadequate or not enough eyelashes.

What is Latisse® solution?

Latisse® solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.

Who should NOT take Latisse®?

Do not use Latisse® solution if you are allergic to one of its ingredients.

Are there any special warnings associated with Latisse® use?

Latisse® solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. Refer to Illustration 2 below. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN® or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use Latisse® under the close supervision of your physician.

Latisse® use may cause darkening of the eyelid skin which may be reversible. Latisse® use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

It is possible for hair growth to occur in other areas of your skin that Latisse® frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using Latisse®.

Who should I tell that I am using Latisse®?

You should tell your physician you are using Latisse® especially if you have a history of eye pressure problems.

You should also tell anyone conducting an eye pressure screening that you are using Latisse®.

What should I do if I get Latisse® in my eye?

Latisse® solution is an ophthalmic drug product. Latisse® is not expected to cause harm if it gets into the eye proper. Do not attempt to rinse your eye in this situation.

What are the possible side effects of Latisse®?

The most common side effects after using Latisse® solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. Latisse® solution may cause other less common side effects which typically occur on the skin close to where Latisse® is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.

If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your physician's advice concerning the continued use of Latisse® solution.

What happens if I stop using Latisse®?

If you stop using Latisse®, your eyelashes are expected to return to their previous appearance over several weeks to months.

Any eyelid skin darkening is expected to reverse after several weeks to months.

Any darkening of the colored part of the eye known as the iris is NOT expected to reverse and is likely permanent.

How do I use Latisse®?

The recommended dosage is one application nightly to the skin of the upper eyelid margin at the base of the eyelashes only.

Once nightly, start by ensuring your face is clean, makeup and contact lenses are removed. Remove an applicator from its tray. Then, holding the sterile applicator horizontally, place one drop of Latisse® on the area of the applicator closest to the tip but not on the tip (see Illustration 1). Then immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part (see Illustration 2). Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use.

Repeat for the opposite upper eyelid margin using a new sterile applicator. This helps minimize any potential for contamination from one eyelid to another.

Illustration 1

Illustration 2

DO NOT APPLY in your eye or to the lower lid. ONLY use the sterile applicators supplied with Latisse® to apply the product. If you miss a dose, don't try to “catch up.” Just apply Latisse® solution the next evening. Fifty percent of patients treated with Latisse® in a clinical study saw significant improvement by 2 months after starting treatment.

If any Latisse® solution gets into the eye proper, it is not expected to cause harm. The eye should not be rinsed.

Don't allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination by common bacteria known to cause infections.

Contact lenses should be removed prior to application of Latisse® and may be reinserted 15 minutes following its administration.

Use of Latisse® more than once a day will not increase the growth of eyelashes more than use once a day.

Store Latisse® solution at 36°-77°F (2°-25°C).

General Information about Latisse®

Prescription treatments are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Latisse® solution for a condition for which it was not prescribed. Do not give Latisse® to other people. It may not be appropriate for them to use.

This leaflet summarizes the most important information about Latisse® solution. If you would like more information, talk with your physician. You can also call Allergan's product information department at 1-800-678-1605.

What are the ingredients in Latisse®?

Active ingredient: bimatoprost

Inactive ingredients: benzalkonium chloride; sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 - 7.8.

© 2017 Allergan. All rights reserved.
All trademarks are the property of their respective owners.
Patented. See: www.allergan.com/patents
Irvine, CA 92612
Made in the U.S.A.

72303US17

NDC 0023-3616-70

Latisse ®

(bimatoprost ophthalmic
solution) 0.03%
Rx only
STERILE R
ALLERGAN
Contents:
One 3 mL bottle of sterile solution
70 disposable applicators

Latisse  
bimatoprost solution/ drops
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0023-3616
Route of Administration OPHTHALMIC DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
bimatoprost (bimatoprost) bimatoprost 0.3 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
benzalkonium chloride  
sodium chloride  
sodium phosphate, dibasic  
citric acid monohydrate  
water  
Packaging
# Item Code Package Description
1 NDC:0023-3616-04 1 BOTTLE, DROPPER in 1 CARTON
1 3 mL in 1 BOTTLE, DROPPER
2 NDC:0023-3616-03 1 BOTTLE, DROPPER in 1 CARTON
2 3 mL in 1 BOTTLE, DROPPER
3 NDC:0023-3616-81 1 BOTTLE, DROPPER in 1 CARTON
3 3 mL in 1 BOTTLE, DROPPER
4 NDC:0023-3616-16 1 BOTTLE, DROPPER in 1 CARTON
4 1.5 mL in 1 BOTTLE, DROPPER
5 NDC:0023-3616-80 1 BOTTLE, DROPPER in 1 CARTON
5 3 mL in 1 BOTTLE, DROPPER
6 NDC:0023-3616-05 1 BOTTLE, DROPPER in 1 CARTON
6 5 mL in 1 BOTTLE, DROPPER
7 NDC:0023-3616-70 1 BOTTLE, DROPPER in 1 CARTON
7 3 mL in 1 BOTTLE, DROPPER
8 NDC:0023-3616-71 1 BOTTLE, DROPPER in 1 CARTON
8 3 mL in 1 BOTTLE, DROPPER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA022369 01/26/2009
Labeler - Allergan, Inc. (144796497)
Establishment
Name Address ID/FEI Operations
Allergan, Inc. 362898611 MANUFACTURE(0023-3616)
Revised: 07/2017   Allergan, Inc.

What other drugs will affect Latisse?

It is not likely that other drugs you take orally or inject will have an effect on topically applied bimatoprost. But many drugs can interact with each other. Tell each of your health care providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

(web3)